» Articles » PMID: 32960261

Radiation Therapy Enhanced Therapeutic Efficacy of Anti-PD1 Against Gastric Cancer

Overview
Journal J Radiat Res
Date 2020 Sep 22
PMID 32960261
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation therapy is an important method in tumor treatment with distinct responses. This study aimed to investigate the immune effects of radiation therapy on the syngeneic gastric tumor model. Mouse forestomach carcinoma (MFC) cells were irradiated with different X-ray doses. Cell proliferation was determined by clonogenic assay. Gene and protein expression were determined by real-time quantitative PCR and western blot, respectively. The tumor model was established by subcutaneously injecting tumor cells in 615-(H-2 K) mice. Levels of immune-related factors in tumor tissues were determined by immunohistochemistry and flow cytometry. 5 Gy × 3 (three subfractions with 4 h interval) treatment significantly inhibited cell proliferation. Protein expression of stimulator of interferon genes (Sting) and gene expression of IFNB1, TNFα as well as CXCL-9 significantly increased in MFC cells after irradiation. In the MFC mouse model, no obvious tumor regression was observed after irradiation treatment. Further studies showed Sting protein expression, infiltration of dendritic cells and T cells, and significantly increased PD-1/PD-L1 expression in tumor tissues. Moreover, the irradiation treatment activated T cells and enhanced the therapeutic effects of anti-PD1 antibody against MFC tumor. Our data demonstrated that although the MFC tumor was not sensitive to radiation therapy, the tumor microenvironment could be primed after irradiation. Radiation therapy combined with immunotherapy can greatly improve anti-tumor activities in radiation therapy-insensitive tumor models.

Citing Articles

Association between adjuvant radiotherapy in adults with gastric cancer and risk of second primary malignancy: a retrospective cohort study using the Surveillance, Epidemiology and End Results database.

Li Z, Li Z, Sun C, Zhang X, Fei H, Xing C BMJ Open. 2025; 15(2):e086349.

PMID: 39938963 PMC: 11822440. DOI: 10.1136/bmjopen-2024-086349.


Programmed death receptor-1/programmed death-ligand 1 inhibitors: Clinical progress and biomarker exploration in gastric cancer.

Shi J, Song X, Gao Z, Dai D, Ding F, Wu X Heliyon. 2024; 10(20):e38710.

PMID: 39640802 PMC: 11620122. DOI: 10.1016/j.heliyon.2024.e38710.


The cGAS/STING Pathway-A New Potential Biotherapeutic Target for Gastric Cancer?.

Tian M, Zhang S, Tan F J Pers Med. 2024; 14(7).

PMID: 39063990 PMC: 11277918. DOI: 10.3390/jpm14070736.


Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors.

Wu Y, Yi M, Niu M, Zhou B, Mei Q, Wu K Cancer Commun (Lond). 2024; 44(7):739-760.

PMID: 38837878 PMC: 11260771. DOI: 10.1002/cac2.12576.


Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity.

Liu S, Wang W, Hu S, Jia B, Tuo B, Sun H Cell Death Dis. 2023; 14(10):679.

PMID: 37833255 PMC: 10575861. DOI: 10.1038/s41419-023-06211-2.


References
1.
Huber J, Farrar J . Regulation of effector and memory T-cell functions by type I interferon. Immunology. 2011; 132(4):466-74. PMC: 3075500. DOI: 10.1111/j.1365-2567.2011.03412.x. View

2.
Yang X, Zhang X, Fu M, Weichselbaum R, Gajewski T, Guo Y . Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell. 2014; 25(1):37-48. PMC: 3927846. DOI: 10.1016/j.ccr.2013.12.004. View

3.
Hoskin P, Bhattacharya I . Protons and more: state of the art in radiotherapy. Clin Med (Lond). 2014; 14 Suppl 6:s61-5. DOI: 10.7861/clinmedicine.14-6-s61. View

4.
Weichselbaum R, Liang H, Deng L, Fu Y . Radiotherapy and immunotherapy: a beneficial liaison?. Nat Rev Clin Oncol. 2017; 14(6):365-379. DOI: 10.1038/nrclinonc.2016.211. View

5.
Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A . STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014; 41(5):843-52. PMC: 5155593. DOI: 10.1016/j.immuni.2014.10.019. View